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or the past 2 years, a team of investigators from the Cen-
ters for Disease Control and Prevention (CDC) has collab-
orated with scientists from the National Institutes of Health
(NIH), the Food and Drug Administration, the Department of
Defense (DOD), academic centers, and international partners
to undertake a research agenda on variola virus, the etiologic
agent of smallpox. Objectives of the program derive from a
1999 Institute of Medicine report that addressed the scientific
needs for live variola virus (1). Progress in addressing these
objectives has been peer reviewed annually by both a select
committee organized by CDC and the World Health Organiza-
tion (WHO) Advisory Committee on Variola Virus Research
(2,3). A summary of accomplishments from the first year’s
efforts was published in 2001 (4). 
The events of September 11, 2001, coupled with the use of
Bacillus anthracis as a bioterrorist weapon of mass destruc-
tion, have substantially increased concerns that variola virus
may be similarly used and have added a sense of urgency to
production of a new smallpox vaccine and to carrying out the
smallpox research agenda. This report provides an update on
progress during 2001.
Vaccine
CDC has worked closely with the manufacturer of Dryvax
(Wyeth, Marietta, PA), the 20-year-old smallpox vaccine held
in stockpile, to ready all 15.4 million doses of vaccine for
immediate distribution. Stocks of this vaccine were retested
for potency by the manufacturer and with very few exceptions
were found to remain fully potent. However, problems were
detected with the diluent used to rehydrate the freeze-dried
vaccine, and consequently all diluent has been replaced. A
recent NIH study found that Dryvax vaccine could be diluted
1:5 and 1:10 and remain fully potent when administered to
vaccinia-naïve persons (5). Either a 1:5 or 1:10 dilution of vac-
cine can be made in the original vaccine container, without the
necessity of transfer to larger vials. Emergency vaccination
plans now call for the vaccine to be used at a 1:5 dilution; thus,
the existing stockpile could protect approximately 75 million
persons. Sufficient additional diluent and needles are being
purchased to support administration of the 75 million doses of
vaccine. 
To ensure that sufficient vaccine becomes available to pro-
tect the entire U.S. population, a contract established in 2000
by CDC with Acambis (Cambridge, MA) to produce and
maintain a stockpile of 40 million doses of a new, MRC-5 (a
diploid human lung cell line suitable for the production of viral
vaccines) cell-culture–grown vaccinia vaccine was modified
to reflect the need for expanded and accelerated production
and human testing. The revised goal is now to produce >50
million doses by the end of 2002, with increased surge capac-
ity for production of >180 million doses annually from 2003
on. Pilot lot production of the new vaccine is now under way,
as are Phase 1 clinical trials. Phase 2 and 3 clinical trials are
scheduled to begin later in 2002. Acambis expects to license
the new vaccine by the end of 2003; however, it will be avail-
able for emergency use as an Investigational New Drug (IND)
product as soon as it is manufactured. A second contract has
been awarded to Acambis, in partnership with Baxter (Vienna,
Austria), for production of 155 million doses of Vero cell-cul-
ture–produced vaccinia vaccine, for delivery by the end of
2002. The expanded use of the Dryvax vaccine, coupled with
production of new vaccine from these two contracts, should
result in sufficient vaccine for the entire U.S. population by the
end of 2002.
Vaccinia vaccine is known to produce adverse events in a
small number of recipients (6). In the spring of 2001, inter-
ested parties met to discuss management of vaccinia vaccine
adverse events. Among the findings was the need to produce
substantially larger stocks of vaccinia immune globulin, and
suppliers are now being sought to produce approximately
30,000 adult treatment doses. 
Antiviral Drugs
An important recommendation from the Institute of Medi-
cine report (1) was to identify antiviral drugs with activity
against variola and related orthopoxviruses. The research team
has been working toward the goal of identifying two distinct
antiviral drugs with different mechanisms of action and effec-
tiveness in the treatment of smallpox infection. One candidate,
cidofovir, has been identified and its activity against variola
virus demonstrated in in vitro assays. During 2001, an IND
was filed for use of cidofovir in both the treatment of acute
smallpox infection and the management of adverse events
*Centers for Disease Control and Prevention, Atlanta, Georgia, USA;
†National Institutes of Health, Bethesda, Maryland, USA; ‡Stanford
University, Stanford, California, USA; and §U.S. Army Medical
Research Institute of Infectious Diseases, Fort Detrick, Frederick,
Maryland, USA
FRESEARCH UPDATE
744 Emerging Infectious Diseases  •  Vol. 8, No. 7, JuLY 2002
associated with vaccinia immunization. The team examined
selected analogs of cidofovir and found some to be 25- to 150-
fold more active than the parent compound in in vitro assays.
These promising candidates will be included in future assays
with animal models. More than 700 additional candidate anti-
viral drug compounds have been screened by in vitro assays
for activity to various orthopoxviruses. Of these, >20 were
found to hold promise against vaccinia and variola viruses and
will be tested in animal models. In addition, Eli Lilly and
Company (Indianapolis, IN) has provided access to agents
from their portfolio of compounds for screening against vari-
ola virus. Access to such compounds, which are already being
used in humans and routinely produced, could dramatically
accelerate efforts to identify antiviral compounds that would
be useful against vaccinia and variola viruses. 
Diagnostic Tests
The team continues to develop and validate assays to rap-
idly and accurately diagnose smallpox infection and the pres-
ence of variola virus, including protein-based tests to identify
variola virus antigen and antivariola immunoglobulins, as well
as specific nucleic acid detection tests. However, validation of
prototype assays is hampered by the lack of access to relevant
human clinical samples. DOD and international collaborating
scientists worked successfully to identify a panel of mono-
clonal and polyclonal antibodies for detection and diagnosis of
variola virus. An assay was developed for rapid and specific
identification of variola virus with polymerase chain reaction
(PCR) probes targeted to variola gene sequences. When these
probes were used in the Smart Cycler (Cepheid, Sunnyvale,
CA)/ TaqMan (Roche Molecular Systems, Inc., Indianapolis,
IN) format, the limit of detection was validated by using the
Bangladesh 1975 variola isolate and found to be approxi-
mately 483 copies. The assay was evaluated in a blinded study
with 164 samples that included genomic DNA from 40 isolates
of variola and 8 isolates of other orthopoxviruses at concentra-
tions ranging from 0.1 to 10,000 pg/µL. No false-positive
reactions were detected with any of the 37 nonvariola samples
(100% specificity). Of the 127 samples containing variola
DNA, 10 were considered negative, all at concentrations of
<10 pg. The overall sensitivity was 92% at a limit of detection
of 0.1 pg and 95% at a limit of detection of 1.0 pg. Preliminary
data indicate that the assay is compatible with the ABI 7700
(Perkin-Elmer, Applied Biosystems Division, Foster City, CA)
and the Light Cycler (Roche Diagnostic Corp., Indianapolis,
IN) platforms, as well as colorimetric and electrochemical
PCR enzyme-linked immunosorbent assay platforms. Collabo-
rative work is continuing to evaluate and validate the assay to
these various platforms.
Genetic Diversity of Variola Virus
The need for additional sequence analyses of variola virus
isolates was recognized both by the Institute of Medicine
expert review (1) and the WHO Advisory Committee on Vari-
ola Virus Research Expert Committee on Orthopoxviruses.
The WHO committee specifically recommended that, at a min-
imum, isolates from Congo and Somalia be fully sequenced
before final destruction of variola virus. The team has devel-
oped a standardized method to extend PCR-restriction frag-
ment-length polymorphism (RFLP) for the detection and
differentiation of variola virus strains. From the WHO collec-
tion held at CDC, 45 variola isolates were selected on the basis
of diverse geographic distribution and year of isolation.
Twenty consensus primer pairs were used to produce 20 over-
lapping amplicons, which include 99.9% of the variola
genome. The amplicons were digested with restriction endonu-
clease and resolved on acrylamide gradient gels, and the
resulting RFLP patterns of the amplicons from the 45 isolates
were compared. A composite dendrogram of all amplicon
RFLP profiles differentiates variola major from variola minor,
and the subclades within variola virus were generally clustered
according to their geographic location or epidemiologic his-
tory. Unique RFLP patterns are generated on different ampli-
cons of the variola isolates; these patterns can be used to
differentiate variola strains and may be highly informative in
epidemiologic studies. A database being built may also help in
rapid recognition of variola or other orthopoxviruses that have
been genetically engineered by the insertion of foreign genes. 
On the basis of the WHO expert committee recommenda-
tions and the degree of diversity identified through the RFLP
analyses, the team determined complete genomic sequences
for eight isolates of variola virus from the WHO collection
(named by geographic area and year of collection: Congo 70,
Somalia 77, Nepal 73, India 64, Sumatra 70, Afghan 70, Horn
70, and Bangladesh 75). In addition to determining the full-
length sequence of the most diverse isolates of variola virus,
sequencing has been completed for >30 genes encoding vari-
ous proteins from the other 37 isolates examined from the col-
lection. All results and analyses are being integrated into a
poxvirus-specific relational database suitable for public access
(www.poxvirus.org). Finally, a new proteomics facility is
being established at CDC to facilitate further characterization
of variola virus isolates with the goal of providing essential
information to assist in the rational design of antiviral drugs
and therapeutic interventions. This facility is scheduled to be
fully functional during 2002.
Animal Model for Smallpox
Clinical manifestations of human smallpox are well
described (6). However, attempts to establish an animal model
that faithfully replicates human smallpox have historically
been unsuccessful. In 2002, the interagency team began evalu-
ation of nonhuman primate models to facilitate in vivo evalua-
tion of antiviral drugs and other therapeutic interventions. A
valid animal model will generate important clinical material to
assist in validating smallpox diagnostic tests and will allow
detailed investigation of the pathogenesis of smallpox infec-
tion. Earlier efforts had succeeded in infecting cynomolgus
macaques with variola virus but failed to produce clinical ill-
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additional monkeys through a combination of both intravenous
injection and aerosol exposure to high-titered (109 PFU) vari-
ola virus succeeded in inducing infection, which led to fatal
disease after a clinical course like that of smallpox in humans.
Subsequent infections by the intravenous route alone led to
fatal infection at only the highest infecting dose (109 PFU),
although monkeys receiving lower doses (106 to 109 PFU) did
show evidence of variola infection, and virus dose was corre-
lated with severity of disease course (7). Distribution of viral
antigens by immunohistochemistry was correlated with repli-
cating viral particles, observed by electron microscopy, and
pathologic lesions resembling human smallpox. Analysis of
daily specimens allowed detection of viral genomes in periph-
eral blood leukocytes and throat fluids by TaqMan PCR within
48 hours of exposure, suggesting the possibility of definitive
diagnosis of smallpox during the prodrome. Overall, these
results suggest that a valid animal model for smallpox may be
feasible.
Collaborative studies with scientists from Stanford Univer-
sity allowed application of high-density DNA microarrays to
measure and classify gene expression and to study the behav-
ior of many genes simultaneously in monkeys experimentally
infected with variola virus. Peripheral blood mononuclear cells
were obtained from monkeys on the day of infection and mul-
tiple subsequent days. Gene expression analysis identified dra-
matic, highly choreographed response patterns and revealed
several biological themes that appeared to be related to the
outcome of infection (K. Rubins et al., Stanford University,
unpub. data). Additional experimental infections of nonhuman
primates with variola and other orthopoxviruses will be con-
ducted. Potential benefits of host genome-wide expression
profiling include early detection of infected persons, recogni-
tion of prognostic markers, rational development of novel
therapeutic and prophylactic strategies, and determination of
early signatures of a protective immune response to vaccina-
tion.
The team has continued investigating whether human
chemokine receptors are involved as host factors in orthopox-
virus infections. Orthopoxviruses have no known unique viral
attachment protein or cell surface receptor. Chemokine recep-
tors, which are on the surface of leukocytes, are involved in
directing leukocytes into areas of inflammation; other patho-
gens are known to use these receptors for cell entry. To deter-
mine the potential role of chemokines and their receptors in
the pathogenesis of variola infection, experiments were per-
formed by using a cell line transfected with genes encoding
human CD4 receptors and subsequently transfected with
human chemokine receptors. In low-multiplicity infection, the
growth rate of variola was enhanced when human chemokine
receptors were expressed. These and other observations sug-
gest a possible role for chemokine receptors in the net growth
and spread of variola virus. Investigations of the role of
chemokines in the pathogenesis of variola infection will
continue.
Conclusion
World Health Assembly resolution WHA52.10 called for
the destruction of all remaining stocks of variola virus by the
end of 2002; however, a recent WHO review of research
progress concluded that the live virus would be required
beyond that date, a position supported by the 55th World
Health Assembly (8,9). Specific scientific priorities that
remain to be addressed include 1) obtaining further sequence
data from the terminal regions of additional variola isolates, 2)
continuing efforts to effectively detect variola virus infection
and validate these procedures, 3) developing new drugs for
smallpox treatment, 4) developing less reactogenic vaccines to
protect against smallpox infection, and 5) validating an animal
model of human smallpox to allow assessment of candidate
drugs and vaccines for both efficacy and regulatory purposes.
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